Table 3.

Association of TACSTD2 methylation and clinicopathological parameters with recurrence free survival in bivariate survival analysis

	HR (95% CI)	p-value
TACSTD2 methylation	2.85 (1.14–7.12)	0.025
Metastasis	4.92 (1.95–12.43)	0.001
TACSTD2 methylation	2.85 (1.14–7.16)	0.026
Tumor stage*	2.77 (1.10–6.95)	0.030
TACSTD2 methylation	3.59 (1.42–9.04)	0.007
Differentiation	11.48 (4.13–31.91)	< 0.001
TACSTD2 methylation	2.37 (0.93–5.99)	0.069
State of Disease**	4.72 (1.65–13.50)	0.004
TACSTD2 methylation	3.39 (1.37–8.35)	0.008
Age	0.99 (0.95–1.03)	0.571

HR hazard ratio; 95% CI 95% confidence interval

*Low defined as T1 and T2; high defined as T3 and T4

**Localized disease defined as pT ≤ 2, N0, M0; Advanced disease defined as pT ≥ 3 and/or N1, M1